Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone/Salmeterol vs Salmeterol in COPD Exacerbations
NCT00144911Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Primary completion
- Dec 2006
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of fluticasone propionate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Annual Rate of Moderate/Severe Exacerbations at 52 weeks. Started Oct 2004; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00144911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144911.